-
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- October 25, 2026
- Posted by:
- Category: Lawyers
No Comments
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI…
-
NUH OPHTHALMOLOGY AT 40: FOUR DECADES OF TRANSFORMING EYE CARE
- October 23, 2026
- Posted by:
- Category: Lawyers
The Department marks its anniversary by spotlighting innovations in multidisciplinary and minimally invasive care, alongside a flagship international congress that fosters global collaboration in ophthalmologySINGAPORE, Oct. 23, 2026 /PRNewswire/ — As the Department of Ophthalmology at the National…
-
Smarter Cars, Robots and Disease Prevention: WSTDF Examines How Future Industries Take Shape
- October 22, 2026
- Posted by:
- Category: Lawyers
CHONGQING, China, Oct. 21, 2026 /PRNewswire/ — A news report from iChongqing. The 2026 World Science and Technology Development Forum opened in Chongqing on October 21, bringing together around 800 participants, including experts and scholars, to explore how automotive technology,…